India To Cap Prices For 108 Heart, Diabetes Formulations Not On Usual List
This article was originally published in PharmAsia News
Executive Summary
The prices of at least nine heart and diabetes drugs are about to become as much as 35% cheaper to India patients as the National Pharmaceutical Pricing Authority uses an obscure provision in the pricing laws.